Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Lenalidomide and Conventional Chemotherapy in Acute Myeloid Leukemia

NCT01132586 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01132586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01132586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Lenalidomide and Conventional Chemotherapy in Acute Myeloid Leukemia
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2010
Completion date
January 31, 2014
Enrollment
61 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia arising from previous myelodysplastic syndrome, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21)(q22;q22); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22;q23); mllt3-mll, adult acute promyelocytic leukemia with t(15;17)(q22;q12); pml-rara, alkylating agent-related acute myeloid leukemia, de novo myelodysplastic syndrome, previously treated myelodysplastic syndrome, recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia, secondary myelodysplastic syndrome, untreated adult acute myeloid leukemia